A reduction in the frequency of retreatment, a measure that might represent significant cost savings, resulted in a small loss of efficacy irrespective of drug during the study. The findings suggested that the cheaper drug, Avastin, currently not licensed for use in AMD treatment, might be a viable alternative to Lucentis which is licensed.The study went onto say that “the choice of anti-VEGF treatment strategy is less straightforward than previously thought”.
Ahpra reforms: Sexual misconduct on register permanently
Optometrists, ophthalmologists and other registered Australian practitioners proven to have committed sexual misconduct will have this information permanently published against...
